9th September 2019, Pomezia, Italy - IRBM today announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies against a novel…
19th November 2018, Pomezia, Italy – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
4th September 2018, Pomezia, Italy – IRBM, today announced a new agreement in the peptide therapeutics area with Merck & Co. Inc., Kenilworth NJ USA, known as MSD outside the United States and Canada, continuing their long-standing history of collaboration that began in 2010.
31st May, 2018 Pomezia, Italy – IRBM, a global Contract Research Organization, has recruited two new members of staff as part of its global growth strategy. Carlo Toniatti, M.D., Ph.D., has been appointed as the Chief Scientific Officer, bringing more than two decades of drug development and discovery experience to the role where he will oversee scientific strategy, and Heidi Kingdon-Jones has been recruited as the Global VP of Sales and Marketing, to drive forward IRBM’s continued global expansion.
August 20th, 2017, WASHINGTON, D.C. – At a ceremony prior to the American Chemical Society fall meeting, the ACS inducted Dr. Vincenzo Summa and Dr. Steven Harper, respectively the Vice President of Drug Discovery and the Head of Medicinal Chemistry at IRBM Science Park S.p.A., into its scientific Hall of Fame as Heroes of Chemistry, 2017. The program recognizes scientists whose innovative work in chemistry and chemical engineering led to commercial products that benefit the world.
June 20th, 2017, MILAN – IRBM announced today that a scientific consortium led by its subsidiary Promidis received a 5.6 million euro grant from the Italian region of Lombardy to discover and develop innovative cures for chronic hepatitis B, a disease which still affects a significant portion of the world population, despite the availability of a vaccine. Chronic hepatitis B is a significant burden on national health systems, and can lead to severe complications, especially in children.
May 18th, 2017, ROME – IRBM Science Park S.p.A., alongside other public and private institutions, has supported the activities of the HDdennomore international network, a group of organizations focused on raising awareness and support for Huntington’s disease sufferers worldwide.
September 15th, 2016, ROME – IRBM Science Park S.p.A. is among eight research institutions, both private and public, which have been awarded the 12.6 million euro grant, BRAVEinMS, issued by the Progressive MS Alliance.
June 30th, 2016, VITERBO (VT) – IRBM’s CNCCS consortium joined the Università della Tuscia, the Italian National Research Council (CNR), and the Italian Department of Instruction, University and Research (MIUR) in announcing the joint PRONAT project, aimed at identifying bioactive agents of animal or plant origin.
June 24th, 2015, ROME – The final results of the Italian- and European-funded AICI project (Approcci Innovativi per il Controllo delle Infezioni, Innovative Approaches for Infection Control), activated in 2013 and carried out by a network of biotech companies such as IRBM Science Park S.p.A., Angelini, Ylichron and IBN Savio, were presented at a final workshop at the Angelini Research Center in St. Palomba (RM).